Similar results were obtained in melanoma patients in whom anti-CTLA-4 efficacy was associated with T cell responses mediated by an overabundance of B. fragilis or Bacteroides thetaiotaomicron[48]. This evidence concerns the gene CTLA4 and melanoma.